EP1490396A4 - Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe - Google Patents

Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe

Info

Publication number
EP1490396A4
EP1490396A4 EP02721225A EP02721225A EP1490396A4 EP 1490396 A4 EP1490396 A4 EP 1490396A4 EP 02721225 A EP02721225 A EP 02721225A EP 02721225 A EP02721225 A EP 02721225A EP 1490396 A4 EP1490396 A4 EP 1490396A4
Authority
EP
European Patent Office
Prior art keywords
immunogeneous
vaccines
reagents
hiv peptides
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02721225A
Other languages
English (en)
French (fr)
Other versions
EP1490396A2 (de
Inventor
Janet M Mcnicholl
Kyle Bond
Busarawan Sriwanthana
Chou-Pong Pau
Anne Degroot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Department Of Medical Sciences Ministry Of Public
Brown University Research Foundation Inc
Government of the United States of America
Original Assignee
Brown University Research Foundation Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown University Research Foundation Inc, US Department of Health and Human Services filed Critical Brown University Research Foundation Inc
Publication of EP1490396A2 publication Critical patent/EP1490396A2/de
Publication of EP1490396A4 publication Critical patent/EP1490396A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP02721225A 2001-03-01 2002-03-01 Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe Withdrawn EP1490396A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27256501P 2001-03-01 2001-03-01
US272565P 2001-03-01
PCT/US2002/006314 WO2002069691A2 (en) 2001-03-01 2002-03-01 Immunogenic hiv peptides for use as reagents and vaccines

Publications (2)

Publication Number Publication Date
EP1490396A2 EP1490396A2 (de) 2004-12-29
EP1490396A4 true EP1490396A4 (de) 2006-04-19

Family

ID=23040344

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02721225A Withdrawn EP1490396A4 (de) 2001-03-01 2002-03-01 Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe

Country Status (4)

Country Link
EP (1) EP1490396A4 (de)
JP (1) JP2004535369A (de)
CA (1) CA2439990A1 (de)
WO (1) WO2002069691A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307130A4 (de) 2000-02-04 2005-01-12 Beth Israel Hospital Impfstoff gegen menschlichen immunschwächevirus
CN101027084B (zh) * 2004-08-17 2012-02-22 古斯达威罗斯研究所 用于调节免疫的突变型hiv nef
ATE401392T1 (de) * 2004-10-04 2008-08-15 Biovaxim Ltd Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
SG170092A1 (en) 2006-03-10 2011-04-29 Peptcell Ltd Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
EP2745845A1 (de) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux Verfahren zur Vorbeugung oder Behandlung einer HIV-Infektion
GB201322574D0 (en) * 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 1 December 1999 (1999-12-01), "immunogenic peptide having a human leukocyte antigen binding motif #441", XP002351895, retrieved from EBI Database accession no. AAY45830 *
DATABASE EMBL 29 September 1999 (1999-09-29), "HIV-derived HLA-binding peptide", XP002351894, retrieved from EBI Database accession no. AAY38258 *

Also Published As

Publication number Publication date
JP2004535369A (ja) 2004-11-25
CA2439990A1 (en) 2002-09-12
EP1490396A2 (de) 2004-12-29
WO2002069691A2 (en) 2002-09-12
WO2002069691A3 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
ATE335722T1 (de) Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel
DE60143301D1 (de) Polyarylcarboxamide zur verwendung als lipidsenker
DE60329983D1 (de) Wachsestersynthase-dna-sequenz, protein und verwendungen davon
DE60101853D1 (de) Schaltungsunabhängige transformation von sensorkonfigurationen zur klassifizierung von personen
CY2011004I2 (el) Χιμαιρικοι λοιμωδεις κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων
DE60202267D1 (de) Occiputplatte und system zur stabilisierung der wirbelsäule
DE60228608D1 (de) Tintenrezepturen und verwendung derselben
DK1680443T3 (da) Stabiliserede alfa-helix-peptider og anvendelser heraf
DE60207053D1 (de) Rekombinante gelatineartige proteine zur verwendung als plasmaexpander
DE60228120D1 (de) Sauerstoffionenleitendes keramikmaterial und verwendung davon
AU2002250078A1 (en) Quantitative epstein barr virus pcr rapid assay
DK1417231T3 (da) Modificeret human thymisk stromal lymphopoietin
DK1923071T3 (da) Equint herpesvirusvaccine
EP1391512A4 (de) Als angiogener marker dienendes polypeptid und dessen dna
EP1490396A4 (de) Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe
DE50107230D1 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
EP1446130A4 (de) Ehrlichia-canis-gene und -impfstoffe
EP1417218A4 (de) Tetrahymena-metallothionein-genpromotor und dessen verwendung
ITRM20010670A1 (it) Piante ricombinanti e costrutti di dna.
EP1457557A4 (de) Neue proteine und deren dnas
SE0102061D0 (sv) New proteins and the corresponding DNA sequences
DE60216434D1 (de) Neues protein und dieses codierende dna
AU2003220067A8 (en) Jade nucleic acids, proteins and uses thereof
EP1384077A4 (de) Isolierte menschliche transporterproteine, menschliche transporterproteine codierende nukleinsäuremoleküle sowie verwendungen davon
AU2002228431A1 (en) Novel protein and dna thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030923

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060307

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEPARTMENT OF MEDICAL SCIENCES MINISTRY OF PUBLIC

Owner name: BROWN UNIVERSITY RESEARCH FOUNDATION

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS

17Q First examination report despatched

Effective date: 20061127

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070411